OncoMatch

OncoMatch/Clinical Trials/NCT06402708

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Is NCT06402708 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Chemotherapy for thymic carcinoma.

Phase 3RecruitingFudan UniversityNCT06402708Data as of May 2026

Treatment: ChemotherapyThe goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance? Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not. Participants will: 1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.

Check if I qualify

Extracted eligibility criteria

Disease stage

Required: Stage I, II, III

Lab requirements

Blood counts

White blood cells ≥ 3 × 10^9/L; Neutrophils ≥ 1.5 × 10^9/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 10^9/L

Kidney function

Creatinine ≤ 1.5 times the upper limit of normal value

Liver function

Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value

Cardiac function

No severe heart dysfunction; Symptomatic coronary heart disease and left heart failure excluded

No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency; White blood cells ≥ 3 × 10^9/L; Neutrophils ≥ 1.5 × 10^9/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 10^9/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify